Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses treatment for premenopausal patients with breast cancer.
The role of mTOR inhibition in breast cancer is evolving, and ongoing studies are evaluating biomarkers that will identify the patients who will benefit.
Ruth O’Regan, MD, discusses the utility of CDK4/6 inhibitors in breast cancer.
Rutika Mehta, MD, MPH, discusses which patients with esophageal squamous cell carcinoma may benefit most from the different frontline treatment options available and highlights key treatment developments with adjuvant immunotherapy plus chemotherapy.
Ryan B. Corcoran, MD, PhD, discusses the presence of HER2 amplification in metastatic colorectal cancer.
Ryan Bookout, PharmD, president, Hematology/Oncology Pharmacy Association, clinical pharmacist, Moffitt Cancer Center, discusses the sustainability of the field of oncology as drug prices continue to rise.
As melanoma becomes more prevalent and more lethal in the United States, a multidisciplinary approach for treating inoperable in-transit metastases has proved to be a viable and valuable option.
Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses combination therapies in non–small cell lung cancer (NSCLC).
Ryan J. Sullivan, MD, discusses the early reduction of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp and shares how these reductions could correlate with longer overall survival in patients with a best response of stable disease.
Pembrolizumab plus concurrent chemoradiation, followed by single-agent pembrolizumab, maintained survival benefits in patients with previously untreated, locally advanced stage III non–small cell lung cancer.
Omid Hamid, MD, and Ryan Sullivan, MD, discuss what they look forward to in the future of metastatic uveal melanoma treatment.
Ryan W. Huey, MD, discusses challenges faced with immunotherapy in hepatocellular carcinoma.
A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.
S. Gail Eckhardt, MD, professor and head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.
S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses an investigational immunotherapy combination being explored in patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.
S. Vincent Rajkumar, a professor of Medicine at the Mayo Clinic, Rochester, Minnesota, discusses the prevalence of quadruplet regimens in treating patients with multiple myeloma.
S. Yousuf Zafar, MD, associate professor of medicine, Duke Cancer Institute, discusses the potential of immunotherapy for the treatment of patients with colorectal cancer (CRC).
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the design of the phase 3 CARTITUDE-4 trial in multiple myeloma.
Saad Z. Usmani, MD, MBA, FACP, discusses the complexity of approaching frontline treatment decisions in patients with high-risk multiple myeloma.